Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00868361 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Absorption, Metabolism and Excretion of Talampanel
A Phase 1 study, sponsored by Teva Branded Pharmaceutical Products R&D.
- Terminated
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT00868361: Clinical Trial Phase 1 study, sponsored by Teva Branded Pharmaceutical Products R&D.
NCT00868361 is a Phase 1 study that was terminated before completion, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 10 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00868361, a Phase 1 study, was terminated before completion, sponsored by Teva Branded Pharmaceutical Products R&D.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the chemical breakdown and excretion of talampanel and its break down products in plasma, feces, and urine of healthy human volunteers.
Interventions
- DRUG Talampanel (non-radiolabeled), [14C] Talampanel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2009-05 |
| Est. Completion | 2009-09 |
| Phase | Phase 1 |
Why NCT00868361 stopped before completion
NCT00868361 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 1 intervention - of which Talampanel (non-radiolabeled), [14C] Talampanel is the first listed.
NCT00868361 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00868361 about?
NCT00868361 is a clinical study titled "A Study to Investigate the Absorption, Metabolism and Excretion of Talampanel". The purpose of this study is to characterize the chemical breakdown and excretion of talampanel and its break down products in plasma, feces, and urine of healthy human volunteers.
What is the current status of trial NCT00868361?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2009-05. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00868361?
The interventions under investigation include: Talampanel (non-radiolabeled), [14C] Talampanel (DRUG).
Who is sponsoring clinical trial NCT00868361?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00868361's enrollment target sits among peer trials
10 1913th of 2000 higher than 46 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia